2023
Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.
Horowitch B, Lee D, Ding M, Martinez-Morilla S, Aung T, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm D, Ishizuka J. Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma. Clinical Cancer Research 2023, 29: 2908-2918. PMID: 37233452, PMCID: PMC10524955, DOI: 10.1158/1078-0432.ccr-23-0215.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHuman melanoma cell linesMelanoma cell linesPD-L1Validation cohortYale-New Haven HospitalCombination of ipilimumabPD-L1 markersImmune checkpoint blockadePD-L1 biomarkerNew Haven HospitalSTAT1 levelsCell linesWestern blot analysisCheckpoint inhibitorsCheckpoint blockadeClinical responseOverall survivalImproved survivalResistance of cancersMetastatic melanomaMelanoma responsePredict responseTreatment responseDistinct patterns
2019
Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy
Zhang J, Sun L, Cui J, Wang J, Liu X, Aung T, Qu Z, Chen Z, Adelson D, Lin L. Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy. Cytometry Part A 2019, 97: 70-77. PMID: 31411813, PMCID: PMC7004076, DOI: 10.1002/cyto.a.23869.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor tyrosine kinase inhibitorsEGFR mutationsGrowth factor receptor tyrosine kinase inhibitorsDrug resistanceReceptor tyrosine kinase inhibitorsEGFR TKI-resistant cellsEGFR-TKI resistanceNew treatment strategiesGefitinib-induced apoptosisAnti-cancer effectsLower survival rateWestern blot analysisMonths treatmentMost patientsNSCLC patientsCell cycle arrestTreatment strategiesHigh incidenceMortality rateSurvival rateCancer leadFlow cytometryPatientsResistant cellsKinase inhibitors